ABSTRACT
Achondroplasia is the most common genetic form of human dwarfism, characterized by midfacial hypoplasia resulting in occlusal abnormality and foramen magnum stenosis, leading to serious neurologic complications and hydrocephalus. Currently, surgery is the only way to manage jaw deformity, neurologic complications, and hydrocephalus in patients with achondroplasia. We previously showed that C-type natriuretic peptide (CNP) is a potent stimulator of endochondral bone growth of long bones and vertebrae and is also a potent stimulator in the craniofacial region, which is crucial for midfacial skeletogenesis. In this study, we analyzed craniofacial morphology in a mouse model of achondroplasia, in which fibroblast growth factor receptor 3 (FGFR3) is specifically activated in cartilage ( Fgfr3ach mice), and investigated the mechanisms of jaw deformities caused by this mutation. Furthermore, we analyzed the effect of CNP on the maxillofacial area in these animals. Fgfr3ach mice exhibited midfacial hypoplasia, especially in the sagittal direction, caused by impaired endochondral ossification in craniofacial cartilage and by premature closure of the spheno-occipital synchondrosis, an important growth center in craniomaxillofacial skeletogenesis. We crossed Fgfr3ach mice with transgenic mice in which CNP is expressed in the liver under the control of the human serum amyloid-P component promoter, resulting in elevated levels of circulatory CNP ( Fgfr3ach/SAP-Nppc-Tg mice). In the progeny, midfacial hypoplasia in the sagittal direction observed in Fgfr3ach mice was improved significantly by restoring the thickness of synchondrosis and promoting proliferation of chondrocytes in the craniofacial cartilage. In addition, the foramen magnum stenosis observed in Fgfr3ach mice was significantly ameliorated in Fgfr3ach/SAP-Nppc-Tg mice due to enhanced endochondral bone growth of the anterior intraoccipital synchondrosis. These results clearly demonstrate the therapeutic potential of CNP for treatment of midfacial hypoplasia and foramen magnum stenosis in achondroplasia.
Subject(s)
Achondroplasia/drug therapy , Jaw Abnormalities/drug therapy , Natriuretic Peptide, C-Type/blood , Natriuretic Peptide, C-Type/pharmacology , Achondroplasia/diagnostic imaging , Achondroplasia/pathology , Animals , In Situ Nick-End Labeling , Jaw Abnormalities/diagnostic imaging , Jaw Abnormalities/pathology , Mice , Osteogenesis/drug effects , Reverse Transcriptase Polymerase Chain Reaction , X-Ray MicrotomographySubject(s)
Diabetes Mellitus , Interleukin-17 , Weight Gain/drug effects , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Blood Glucose/metabolism , Cytokines/metabolism , Diabetes Mellitus/drug therapy , Diabetes Mellitus/physiopathology , Fatty Liver/metabolism , Female , Glycated Hemoglobin/analysis , Humans , Interleukin-17/antagonists & inhibitors , Interleukin-17/metabolism , Middle AgedABSTRACT
C-type natriuretic peptide (CNP) is a potent stimulator of long bone and vertebral development via endochondral ossification. In the present study, we investigated the effects of CNP on craniofacial skeletogenesis, which consists of both endochondral and membranous ossification. Morphometric analyses of crania from CNP knockout and transgenic mice revealed that CNP stimulates longitudinal growth along the cranial length, but does not regulate cranial width. CNP markedly increased the length of spheno-occipital synchondrosis in fetal murine organ cultures, and the thickness of cultured murine chondrocytes from the spheno-occipital synchondrosis or nasal septum, resulting in the stimulation of longitudinal cranial growth. Mandibular growth includes endochondral and membranous ossification; although CNP stimulated endochondral bone growth of condylar cartilage in cultured fetal murine mandibles, differences in the lengths of the lower jaw between CNP knockout or transgenic mice and wild-type mice were smaller than those observed for the lengths of the upper jaw. These results indicate that CNP primarily stimulates endochondral ossification in the craniofacial region and is crucial for midfacial skeletogenesis.
Subject(s)
Facial Bones/drug effects , Natriuretic Peptide, C-Type/pharmacology , Osteogenesis/drug effects , Skull/drug effects , Aggrecans/analysis , Animals , Cartilage, Articular/drug effects , Cell Culture Techniques , Cell Proliferation/drug effects , Cephalometry/methods , Chondrocytes/drug effects , Collagen Type II/genetics , Collagen Type X/analysis , Cranial Sutures/drug effects , Dose-Response Relationship, Drug , Imaging, Three-Dimensional/methods , Mandible/drug effects , Mandibular Condyle/drug effects , Maxilla/drug effects , Mice , Mice, Knockout , Mice, Transgenic , Nasal Cartilages/drug effects , Occipital Bone/drug effects , Organ Culture Techniques , Proliferating Cell Nuclear Antigen/analysis , Skull Base/drug effects , Sphenoid Bone/drug effects , X-Ray Microtomography/methodsABSTRACT
Longitudinal bone growth is determined by endochondral ossification that occurs as chondrocytes in the cartilaginous growth plate undergo proliferation, hypertrophy, cell death, and osteoblastic replacement. The natriuretic peptide family consists of three structurally related endogenous ligands, atrial, brain, and C-type natriuretic peptides (ANP, BNP, and CNP), and is thought to be involved in a variety of homeostatic processes. To investigate the physiological significance of CNP in vivo, we generated mice with targeted disruption of CNP (Nppc(-/-) mice). The Nppc(-/-) mice show severe dwarfism as a result of impaired endochondral ossification. They are all viable perinatally, but less than half can survive during postnatal development. The skeletal phenotypes are histologically similar to those seen in patients with achondroplasia, the most common genetic form of human dwarfism. Targeted expression of CNP in the growth plate chondrocytes can rescue the skeletal defect of Nppc(-/-) mice and allow their prolonged survival. This study demonstrates that CNP acts locally as a positive regulator of endochondral ossification in vivo and suggests its pathophysiological and therapeutic implication in some forms of skeletal dysplasia.
Subject(s)
Dwarfism/metabolism , Natriuretic Peptide, C-Type/metabolism , Animals , Bone and Bones/metabolism , Chondrocytes/metabolism , Chondrocytes/physiology , Disease Models, Animal , Dwarfism/mortality , Female , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Natriuretic Peptide, C-Type/deficiency , Natriuretic Peptide, C-Type/genetics , Ossification, HeterotopicABSTRACT
In a previous study we showed that the involvement of EP4 subtype of the prostaglandin E (PGE) receptor is crucial for lipopolysaccharide (LPS)-induced osteoclast formation in vitro. The present study was undertaken to test whether EP4 is actually associated with LPS-induced bone resorption in vivo. In wild-type (WT) mice, osteoclast formation in vertebrae and tibiae increased 5 days after systemic LPS injection, and urinary excretion of deoxypyridinoline, a sensitive marker for bone resorption, statistically increased 10 days after injection. In EP4 knockout (KO) mice, however, LPS injection caused no significant changes in these parameters throughout the experiment. LPS exposure for 4 h strongly induced osteoclast differentiation factor (ODF) mRNA expression in primary osteoblastic cells (POB) both from WT and EP4 KO mice, and this expression was not inhibited by indomethacin, suggesting prostaglandin (PG) independence. LPS exposure for 24 h further induced ODF expression in WT POB, but not in EP4 KO POB. Indomethacin partially inhibited ODF expression in WT POB, but not in EP4 KO POB. These data suggest that ODF is induced both PG dependently and PG independently. LPS exposure for 24 h induced slightly greater osteoclastgenesis inhibitory factor (OCIF) mRNA expression in EP4 KO than in WT POB. These findings suggest that the reduced ODF expression and apparently increased OCIF expression also are responsible for the markedly reduced LPS-induced osteoclast formation in EP4 KO mice. Our results show that the EP4 subtype of the PGE receptor is involved in LPS-induced bone resorption in vivo also. Since LPS is considered to be largely involved in bacterially induced bone loss, such as in periodontitis and osteomyelitis, our study is expected to help broaden our understanding of the pathophysiology of these conditions.
Subject(s)
Bone Resorption/etiology , Lipopolysaccharides/toxicity , Receptors, Prostaglandin E/physiology , Animals , Carrier Proteins/genetics , Dinoprostone/physiology , Female , Glycoproteins/genetics , Membrane Glycoproteins/genetics , Mice , Mice, Inbred C57BL , Mice, Knockout , Osteoblasts/metabolism , Osteocalcin/blood , Osteoprotegerin , RANK Ligand , RNA, Messenger/analysis , Receptor Activator of Nuclear Factor-kappa B , Receptors, Cytoplasmic and Nuclear/genetics , Receptors, Tumor Necrosis FactorABSTRACT
Brain natriuretic peptide (BNP), a hormone produced primarily by the cardiac ventricle, is thought to be involved in a variety of homeostatic processes through its cognate receptor, guanylyl cyclase A (GC-A). We previously created transgenic mice overexpressing BNP under the control of the liver-specific human serum amyloid P component promoter (BNP-transgenic mice) and demonstrated that they exhibit reduced blood pressure and cardiac weight accompanied by an elevation of plasma cGMP concentrations and marked skeletal overgrowth through the activation of endochondral ossification. To address whether BNP exerts its biological effects solely through GC-A, we produced BNP-transgenic mice lacking GC-A (BNP-Tg/GC-A-/- mice) and examined their cardiovascular and skeletal phenotypes. The GC-A-/- mice are hypertensive with cardiac hypertrophyrelative to wild-type littermates, which is not alleviated by overexpression of BNP in BNP-Tg/GC-A-/- mice. The BNP-Tg/GC-A-/- mice, however, continue to exhibit marked longitudinal growth of vertebrae and long bones comparably to BNP-Tg mice. This study provides genetic evidence that BNP reduces blood pressure and cardiac weight through GC-A, whereas it dramatically alters endochondral ossification in the absence of this receptor. Therefore, the BNP-Tg/GC-A-/- mice provide the first experimental model demonstrating that this natriuretic peptide can signal in a tissue-specific manner through a receptor other than GC-A.
Subject(s)
Natriuretic Peptide, Brain/physiology , Receptors, Cell Surface/physiology , Signal Transduction/physiology , Animals , Atrial Natriuretic Factor/blood , Bone and Bones/metabolism , Bone and Bones/physiology , Cardiovascular Physiological Phenomena , Cyclic GMP/blood , Cyclic GMP/metabolism , Cyclic GMP/urine , Guanylate Cyclase/deficiency , Guanylate Cyclase/genetics , Guanylate Cyclase/physiology , Heart Ventricles , Isoenzymes/genetics , Isoenzymes/physiology , Mice , Mice, Knockout/genetics , Mice, Transgenic/genetics , Myocardium/metabolism , Natriuretic Peptide, Brain/blood , Natriuretic Peptide, Brain/genetics , Osmolar Concentration , PhenotypeABSTRACT
Prostaglandin E2 (PGE2) exerts its effects through the PGE receptor that consists of four subtypes (EP1, EP2, EP3, and EP4). Osteoclast formation in the coculture of primary osteoblastic cells (POB) and bone marrow cells was enhanced more by 11-deoxy-PGE1 (an EP4 and EP2 agonist) than by butaprost (an EP2 agonist) and other agonists, which suggests that EP4 is the main factor in PGE2-induced osteoclast formation. PGE2-induced osteoclast formation was not observed in the coculture of POB from EP4-deficient (EP4 k/o) mice and spleen cells from wild-type (w/t) mice, whereas osteoclasts were formed in the coculture of POB from w/t mice and spleen cells from EP4-k/o mice. In situ hybridization (ISH) showed that EP4 messenger RNA (mRNA) was expressed on osteoblastic cells but not on multinucleated cells (MNCs) in w/t mice. These results indicate that PGE2 enhances osteoclast formation through its EP4 subtype on osteoblasts. Osteoclast formation by interleukin 1alpha (IL-1alpha), tumor necrosis factor alpha (TNF-alpha), basic fibroblast growth factor (bFGF), and lipopolysaccharide (LPS) was hardly observed in the coculture of POB and bone marrow cells, both from EP4-k/o mice, which shows the crucial involvement of PG and the EP4 subtype in osteoclast formation by these molecules. In contrast, osteoclast formation by 1,25-hydroxyvitamin D3 (1,25(OH)2D3) was not impaired and that by parathyroid hormone (PTH) was only partially impaired in EP4-k/o mice, which may be related to the fact that EP4-k/o mice revealed no gross skeletal abnormalities. Because it has been suggested that IL-1alpha, TNF-alpha, bFGF, and LPS are involved in inflammatory bone loss, our work can be expected to contribute to an understanding of the pathophysiology of these conditions.
Subject(s)
Cytokines/pharmacology , Lipopolysaccharides/pharmacology , Osteoclasts/physiology , Receptors, Prostaglandin E/physiology , Signal Transduction/drug effects , Animals , Cell Differentiation/physiology , Cells, Cultured , Dinoprostone/physiology , Inflammation , Mice , Mice, Knockout , Osteoclasts/cytology , Receptors, Prostaglandin E/agonists , Receptors, Prostaglandin E, EP4 SubtypeABSTRACT
This study examined which subtype(s) of PGE receptors is involved in the induction of c-fos and c-jun by PGE(2) in MC3T3-E1 cells. We also investigated the possibility that the induction of these genes is involved in the growth and differentiation of this cell line. PGE(2) dose-dependently induced c-fos and c-jun mRNA expressions in MC3T3-E1 cells. Of the PGE analogs, 17-phenyl-omega-trinor PGE(2) (EP(1) agonist) and sulprostone (EP(1)/EP(3) agonist) were far more potent than butaprost (EP(2) agonist) and 11-deoxy PGE(1) (EP(2)/EP(4) agonist) in inducing c-fos and c-jun mRNA expressions. Since MC3T3-E1 cells do not express the EP(3) subtype, these results suggest that PGE(2) induces c-fos and c-jun mRNA expressions through the EP(1) subtype of its receptor. In order to study the functional relevance of these protooncogenes, we then studied the effect of inhibition of their synthesis by the use of antisense oligonucleotide. Alkaline phosphatase (ALP) suppression by 17-phenyl-omega-trinor PGE(2) was reversed by antisense oligonucleotide for either c-fos or c-jun. These results suggest that PGE(2), via the EP(1) subtype of the PGE receptor, negatively modulates the transition from proliferation to the matrix maturation stage through the induction of c-fos and c-jun. However, antisense oligonucleotide for c-fos or c-jun did not alter the prostaglandin G/H synthase-2 mRNA expression induced by EP(1). Thus, it is possible that c-fos and c-jun inductions do not account for all the EP(1)-mediated PGE(2) actions in MC3T3-E1 cells.
Subject(s)
Dinoprostone/pharmacology , Genes, fos/genetics , Genes, jun/genetics , Osteoblasts/drug effects , Receptors, Prostaglandin E/physiology , Alkaline Phosphatase/drug effects , Alkaline Phosphatase/metabolism , Animals , Cell Line , Cyclooxygenase 2 , Dinoprostone/analogs & derivatives , Dose-Response Relationship, Drug , Gene Expression Regulation/drug effects , Isoenzymes/genetics , Mice , Oligodeoxyribonucleotides, Antisense/pharmacology , Osteoblasts/cytology , Osteoblasts/metabolism , Prostaglandin-Endoperoxide Synthases/genetics , RNA, Messenger/drug effects , RNA, Messenger/genetics , RNA, Messenger/metabolism , Receptors, Prostaglandin E, EP1 SubtypeABSTRACT
There is recent evidence that natriuretic peptides are important regulators of bone and cartilage, although they were originally identified as the cardiac hormones causing natriuresis and hypotension. Three members of natriuretic peptide family are known: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP). The biologically active receptors for these peptides are particulate guanylate cyclases; the two known types are GC-A and GC-B. ANP and BNP have high affinities for GC-A, and CNP is the preferred ligand for GC-B. In this paper we report the results of our study of the expression and possible role(s) of natriuretic peptides in the ROB-C26 cell, which is an osteogenic cell line with multiple potentials for differentiating into myoblast, osteoblast, and adipocyte. ROB-C26 cells produced cGMP in response to natriuretic peptides at both their basal state and after enhanced differentiation into osteoblast which was induced by bone morphogenetic protein [(BMP)-2]. CNP was far more potent than ANP in cGMP production. In contrast, enhanced differentiation into adipocyte by dexamethasone resulted in the marked decrease in their responsiveness to natriuretic peptides. Although the messages for GC-A and GC-B were demonstrated by Northern blot analysis at both the basal stage and after BMP treatment, they were down-regulated after dexamethasone treatment. The presence of CNP was shown by RT-PCR and immunohistochemistry in ROB-C26 cells. C3H10T1/2, which is another and more primitive mesenchymal cell line, also produced cGMP in response to CNP, and less potently to ANP. Culturing ROB-C26 cells with CNP or 8-bromo cGMP decreased [(3)H]thymidine uptake and slightly increased the message for alkaline phosphatase, which is a marker for osteoblast differentiation. These results suggest that the CNP/GC-B system is preferentially expressed in the cells of osteogenic lineage and their expression is down-regulated with differentiation into adipocyte lineage. The CNP/GC-B system is likely to be an autocrine/paracrine regulator of osteoblast growth and differentiation.
Subject(s)
Dexamethasone/pharmacology , Guanylate Cyclase/metabolism , Natriuretic Peptide, C-Type/metabolism , Osteoblasts/drug effects , Receptors, Atrial Natriuretic Factor , Receptors, Cell Surface/metabolism , Transforming Growth Factor beta , Alkaline Phosphatase/genetics , Alkaline Phosphatase/metabolism , Animals , Atrial Natriuretic Factor/pharmacology , Blotting, Northern , Blotting, Southern , Bone Morphogenetic Protein 2 , Bone Morphogenetic Proteins/pharmacology , Cell Line , Down-Regulation/drug effects , Fluorescent Antibody Technique, Direct , Guanylate Cyclase/genetics , Humans , Natriuretic Peptide, C-Type/genetics , Osteoblasts/metabolism , RNA, Messenger/metabolism , Rats , Receptors, Cell Surface/genetics , Recombinant Proteins/pharmacology , Reverse Transcriptase Polymerase Chain ReactionABSTRACT
The natriuretic peptide family consists of three structurally related endogenous ligands: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP). The biological actions of natriuretic peptides are thought to be mediated through the activation of two guanylyl cyclase (GC)-coupled receptor subtypes (GC-A and GC-B). In this study, we examined the effects of ANP and CNP, which are endogenous ligands for GC-A and GC-B, respectively, on bone growth using an organ culture of fetal mouse tibias, an in vitro model of endochondral ossification. CNP increased the cGMP production much more potently than ANP, thereby resulting in an increase in the total longitudinal bone length. Histological examination revealed an increase in the height of the proliferative and hypertrophic chondrocyte zones in fetal mouse tibias treated with CNP. The natriuretic peptide stimulation of bone growth, which was mimicked by 8-bromo-cGMP, was inhibited by HS-142-1, a non-peptide GC-coupled natriuretic peptide receptor antagonist. The spontaneous increase in the total longitudinal bone growth and cGMP production was also inhibited significantly by HS-142-1. CNP mRNA was expressed abundantly in fetal mouse tibias, where no significant amounts of ANP and BNP mRNAs were detected. A considerable amount of GC-B mRNA was present in fetal mouse tibias. This study suggests the physiologic significance of the CNP/GC-B pathway in the process of endochondral ossification.
Subject(s)
Atrial Natriuretic Factor/physiology , Bone Development , Osteogenesis , Proteins/physiology , Animals , Cyclic AMP/metabolism , Gene Expression , Guanylate Cyclase/genetics , Mice , Natriuretic Peptide, Brain , Natriuretic Peptide, C-Type , Organ Culture Techniques , Peptide Fragments/pharmacology , Receptors, Atrial Natriuretic Factor/genetics , Tibia/embryologyABSTRACT
Prostaglandin E2 (PGE2) is known to autoamplify its production in the osteoblasts through the induction of prostaglandin G/H synthase-2 (PGHS-2), which is the inducible form of the rate-limiting enzyme in PG synthesis, PGHS. To elucidate the cellular mechanism mediating this process, we have employed the PGE2 analogs, which are specific agonists for four subtypes of PGE receptor, and studied the potency of these analogs to induce PGHS-2 mRNA in mouse osteoblastic MC3T3-E1 cells. The induction was mainly observed by 17-phenyl-omega-trinor PGE2 (EP1 agonist) and sulprostone (EP3/EP1 agonist), but not by butaprost (EP2 agonist) or 11-deoxy PGE1 (EP4/EP2 agonist). Since EP3 subtype was undetectable in MC3T3-E1 cells, these data indicate that PGHS-2 mRNA induction is mediated through EP1 subtype of PGE receptor in MC3T3-E1 cells. PGE2 production determined by radioimmunoassay was also increased by 17-phenyl-omega-trinor PGE2 and sulprostone. The autoamplification of PGE2 production is considered to be important in elongating the otherwise short-lived PGE2 action in certain physiological conditions such as mechanical stress and fracture healing, as well as the pathological inflammatory bone loss. The observations in the present study provide us with the better understanding of these processes.
Subject(s)
Dinoprostone/pharmacology , Osteoblasts/cytology , Oxytocics/pharmacology , Receptors, Prostaglandin E/drug effects , 3T3 Cells , Abortifacient Agents, Nonsteroidal/pharmacology , Alprostadil/analogs & derivatives , Alprostadil/pharmacology , Animals , Cyclooxygenase 2 , Dinoprostone/administration & dosage , Dinoprostone/analogs & derivatives , Dinoprostone/genetics , Dose-Response Relationship, Drug , Fibrinolytic Agents/pharmacology , Inositol 1,4,5-Trisphosphate/metabolism , Isoenzymes/drug effects , Isoenzymes/genetics , Mice , Osteoblasts/drug effects , Osteoblasts/metabolism , Oxytocics/administration & dosage , Prostaglandin-Endoperoxide Synthases/drug effects , Prostaglandin-Endoperoxide Synthases/genetics , Prostaglandins E, Synthetic/pharmacology , RNA, Messenger/metabolism , Receptors, Prostaglandin E/classificationABSTRACT
Longitudinal bone growth is determined by the process of endochondral ossification in the cartilaginous growth plate, which is located at both ends of vertebrae and long bones and involves many systemic hormones and local regulators. Natriuretic peptides organize a family of three structurally related peptides: atrial natriuretic peptide, brain natriuretic peptide (BNP), and C-type natriuretic peptide. Atrial natriuretic peptide and BNP are cardiac hormones that are produced predominantly by the atrium and ventricle, respectively. C-type natriuretic peptide occurs in a wide variety of tissues, where it acts as a local regulator. These peptides can influence body fluid homeostasis and blood pressure control through the activation of two guanylyl cyclase (GC)-coupled natriuretic peptide receptor subtypes-GC-A and GC-B. We report here marked skeletal overgrowth in transgenic mice that overexpress BNP. Transgenic mice with elevated plasma BNP concentrations exhibited deformed bony skeletons characterized by kyphosis, elongated limbs and paws, and crooked tails. Bone abnormalities resulted from a high turnover of endochondral ossification accompanied by overgrowth of the growth plate. Studies using an in vitro organ culture of embryonic mouse tibias revealed that BNP increases the height of cartilaginous primordium directly, thereby stimulating the total longitudinal bone growth. The present study demonstrates that natriuretic peptides can affect the process of endochondral ossification.
Subject(s)
Bone Development/genetics , Bone and Bones/abnormalities , Nerve Tissue Proteins/physiology , Osteogenesis/genetics , Aging , Animals , Bone and Bones/pathology , Embryonic and Fetal Development , Humans , Mice , Mice, Transgenic , Natriuretic Peptide, Brain , Nerve Tissue Proteins/blood , Nerve Tissue Proteins/genetics , Organ Culture Techniques , Promoter Regions, Genetic , Recombinant Fusion Proteins/biosynthesis , Serum Amyloid P-Component/biosynthesis , Serum Amyloid P-Component/genetics , Tibia/embryology , Tibia/pathologyABSTRACT
Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), which act as cardiac hormones, are produced mainly by the atrium and ventricle, respectively, and are involved in body fluid homeostasis and blood pressure control. The ANP and BNP gene expressions are markedly augmented in ventricles of patients with a wide variety of cardiovascular diseases. It has been demonstrated that the ANP and BNP genes are tightly linked on mouse chromosome 4 and on the distal short arm of human chromosome 1. However, the precise physical map of the ANP and BNP genes has never been elucidated. In the present study, we characterized the genomic DNA fragment containing the ANP and BNP genes in mice and humans. Three genomic DNA clones harboring the entire mouse BNP gene were isolated from a 129/Sv mouse genomic DNA library. Nucleotide sequence analysis revealed that a phage clone (lambda mBNP #3) contains at its 3'-end the 5'-flanking region and the first 209-bp sequence of the first exon of the mouse ANP gene. In mice, the BNP gene was located about 12 kb upstream of the ANP gene. By polymerase chain reaction, we isolated an approximately 11-kb human genomic DNA fragment containing the third exon of the BNP gene and the first and second exons of the ANP gene. In humans, the BNP gene was located upstream of the ANP gene, approximately 8 kb apart. The present study provides the direct evidence that the ANP and BNP genes are organized in tandem in the mouse and human genomes.
Subject(s)
Atrial Natriuretic Factor/genetics , Chromosomes, Human, Pair 1 , Genetic Linkage , Genome, Human , Genome , Nerve Tissue Proteins/genetics , Animals , Chromosome Mapping , DNA Fragmentation , Humans , Mice , Molecular Sequence Data , Natriuretic Peptide, Brain , Sequence Analysis, DNAABSTRACT
A 59-year-old man visited Kyoto University Hospital because of general malaise, polyuria, and polydipsia. The diagnosis of primary hyperparathyroidism was made based on hypercalcemia and an elevated circulating PTH level. A nodule was palpable in the left anterior neck. Two weeks later, the serum calcium level was normalized and his symptoms subsided. A temporary expansion, followed by reduction of the tumor size was observed by serial ultrasonography. Histology of the resected tumor showed central necrotic tissue, with some peripherally remaining glandular tissue. We report here a rare case of primary hyperparathyroidism with spontaneous remission due to hemorrhagic infarction in the adenoma.
Subject(s)
Adenoma/complications , Hemorrhage/complications , Hyperparathyroidism/complications , Infarction/complications , Parathyroid Neoplasms/complications , Adenoma/diagnostic imaging , Adenoma/pathology , Alkaline Phosphatase/blood , Calcium/blood , Humans , Hyperparathyroidism/blood , Magnetic Resonance Imaging , Male , Middle Aged , Parathyroid Hormone/blood , Parathyroid Neoplasms/diagnostic imaging , Parathyroid Neoplasms/pathology , Remission, Spontaneous , Time Factors , UltrasonographyABSTRACT
A rare case of functioning oxyphil parathyroid adenoma associated with primary hyperparathyroidism and marked hungry bone syndrome was revealed in a 29-year-old man with hypercalcemia and elevated circulating parathyroid hormone (PTH) level. A large parathyroid tumor weighing 8.4 g was resected and proved to be an oxyphil adenoma. Hypocalcemia was sustained after the operation, despite intensive calcium supplementation. During the postoperative 8 months, bone mineral density at the lumbar spine increased dramatically from 0.892 g/cm2 to 1.244 g/cm2, and whole body bone mineral content increased from 1,913.4 g to 2,419.2 g. This case gives insight to the reversibility of bone loss in this disorder.
Subject(s)
Adenoma, Oxyphilic/complications , Bone Diseases/complications , Hyperparathyroidism/complications , Parathyroid Neoplasms/complications , Adenoma, Oxyphilic/surgery , Adult , Bone Density , Bone Diseases/metabolism , Humans , Male , Parathyroid Neoplasms/surgery , Syndrome , Time FactorsABSTRACT
C-type natriuretic peptide (CNP) is a local regulator in the brain and vascular wall. We present data to demonstrate the production and action of CNP in the osteoblast. CNP increased cGMP production, far more potently than atrial natriuretic peptide (ANP) in an osteoblastic cell line, MC3T3-E1. Since ANP and CNP are the ligands for two particulate guanylate cyclases, guanylate cyclase-A (GC-A) and guanylate cyclase-B (GC-B), respectively, these results reveal the expression of GC-B in MC3T3-E1. In addition, CNP mRNA and CNP-like immunoreactivity were detected in cell extracts from MC3T3-E1 and its culture medium, respectively. Both CNP and 8-bromo cGMP dose-dependently decreased [3H]thymidine uptake, without affecting alkaline phosphatase activity. These results indicate that CNP is a novel autocrine/paracrine regulator of osteoblast and suggest the presence of "bone natriuretic peptide system."